Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial
Choices of hypoglycemic agents for patients with type 2 diabetes and chronic kidney disease (CKD) are limited. Available data among patients with CKD suggest that pioglitazone was effective and safe, with no increase in serious adverse effects. However, weight gain and fluid retention are major clin...
Gespeichert in:
| Veröffentlicht in: | PloS one 2018-10, Vol.13 (10), p.e0206722-e0206722 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0206722 |
|---|---|
| container_issue | 10 |
| container_start_page | e0206722 |
| container_title | PloS one |
| container_volume | 13 |
| creator | Satirapoj, Bancha Watanakijthavonkul, Khanin Supasyndh, Ouppatham |
| description | Choices of hypoglycemic agents for patients with type 2 diabetes and chronic kidney disease (CKD) are limited. Available data among patients with CKD suggest that pioglitazone was effective and safe, with no increase in serious adverse effects. However, weight gain and fluid retention are major clinical problems for pioglitazone among patients with CKD. We conducted this study to compare the efficacy and side effects of low dose pioglitazone with standard dose pioglitazone among patients with type 2 diabetes and CKD.
A total of 75 patients with type 2 diabetes and CKD and inadequate glycemic control receiving any pharmacological antidiabetic treatment were randomly assigned to 2 groups. One group consisted of 37 patients treated with standard dose pioglitazone (15 mg/day) and another group consisted of 38 patients treated with low dose pioglitazone (7.5 mg/day). Glycosylated hemoglobinA1c (HbA1c) and metabolic profiles were monitored every 8 weeks for 24 weeks. Body composition was assessed using bio-electrical impedance analysis (BIA).
After 6 months of therapy, HbA1c levels decreased in both standard and low dose pioglitazone groups. The mean changes in HbA1c for standard and low dose pioglitazone were 1.1±1.6 and -1.4±1.5 (P = 0.543), respectively. Compared with low dose pioglitazone, standard dose pioglitazone treatment led to a greater increase in body weight, fat mass, total body water and extracellular water composition. No major adverse effects including hypoglycemia, congestive heart failure and abnormal liver function were identified.
Pioglitazone 7.5 mg once daily treatments presented similar glycemic control to standard dose pioglitazone and exhibited beneficial effects on weight gain and fluid retention among patients with type 2 diabetes and CKD. |
| doi_str_mv | 10.1371/journal.pone.0206722 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_plos_</sourceid><recordid>TN_cdi_plos_journals_2127656611</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d08dc07aaf2d488bbb16393531cd9a88</doaj_id><sourcerecordid>2127948078</sourcerecordid><originalsourceid>FETCH-LOGICAL-c526t-a76fe6c679f62cbcf0ba1e5acede54273bdc128edf52445bf209bf2226217a133</originalsourceid><addsrcrecordid>eNptks9uEzEQxlcIREvhDRBY4tJLgv_senc5IFVVgUqVOABna9YeJw7OerEdqvR1eFEcklYt6sW2PN_3mxl7quo1o3MmWvZ-FTZxBD-fwohzyqlsOX9SHbNe8JnkVDy9dz6qXqS0orQRnZTPqyNBRdv3Qh5Xf76BxbwlMBqC1joNekuCJT5cExMSksmFhXcZbkoaosN6goiGXLu8JCkXF0TziNCNJG8nJJwYBwNmTHuLXsYwOk1-OjPitgQTQsIP5IzEwgprd1PgOow5Bu_LMUcH_mX1zIJP-Oqwn1Q_Pl18P_8yu_r6-fL87GqmGy7zDFppUWrZ9lZyPWhLB2DYgEaDTc1bMRjNeIfGNryum8Fy2peFc8lZC0yIk-rtnjv5kNThfZPijLeykZKxorjcK0yAlZqiW0PcqgBO_bsIcaEgZqc9KkM7o2kLYLmpu24YBiZFLxrBtOmh6wrr4yHbZlij0ViaBv8A-jAyuqVahN-qfGjhNAVwegDE8GuDKau1Sxq9hxHDZl93X3e03eV695_08e7qvUrHkFJEe1cMo2o3c7cutZs5dZi5Yntzv5E70-2Qib9_ltli</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2127656611</pqid></control><display><type>article</type><title>Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Satirapoj, Bancha ; Watanakijthavonkul, Khanin ; Supasyndh, Ouppatham</creator><creatorcontrib>Satirapoj, Bancha ; Watanakijthavonkul, Khanin ; Supasyndh, Ouppatham</creatorcontrib><description>Choices of hypoglycemic agents for patients with type 2 diabetes and chronic kidney disease (CKD) are limited. Available data among patients with CKD suggest that pioglitazone was effective and safe, with no increase in serious adverse effects. However, weight gain and fluid retention are major clinical problems for pioglitazone among patients with CKD. We conducted this study to compare the efficacy and side effects of low dose pioglitazone with standard dose pioglitazone among patients with type 2 diabetes and CKD.
A total of 75 patients with type 2 diabetes and CKD and inadequate glycemic control receiving any pharmacological antidiabetic treatment were randomly assigned to 2 groups. One group consisted of 37 patients treated with standard dose pioglitazone (15 mg/day) and another group consisted of 38 patients treated with low dose pioglitazone (7.5 mg/day). Glycosylated hemoglobinA1c (HbA1c) and metabolic profiles were monitored every 8 weeks for 24 weeks. Body composition was assessed using bio-electrical impedance analysis (BIA).
After 6 months of therapy, HbA1c levels decreased in both standard and low dose pioglitazone groups. The mean changes in HbA1c for standard and low dose pioglitazone were 1.1±1.6 and -1.4±1.5 (P = 0.543), respectively. Compared with low dose pioglitazone, standard dose pioglitazone treatment led to a greater increase in body weight, fat mass, total body water and extracellular water composition. No major adverse effects including hypoglycemia, congestive heart failure and abnormal liver function were identified.
Pioglitazone 7.5 mg once daily treatments presented similar glycemic control to standard dose pioglitazone and exhibited beneficial effects on weight gain and fluid retention among patients with type 2 diabetes and CKD.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0206722</identifier><identifier>PMID: 30379936</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Aged ; Antidiabetics ; Bioelectricity ; Biology and Life Sciences ; Blood Glucose ; Blood pressure ; Blood tests ; Body composition ; Body composition (biology) ; Body fat ; Body water ; Body weight ; Body weight gain ; Clinical medicine ; Clinical trials ; Composition effects ; Congestive heart failure ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetic Nephropathies - blood ; Diabetic Nephropathies - drug therapy ; Disease control ; Dose-Response Relationship, Drug ; Drug dosages ; Edema ; Electrical impedance ; Family medical history ; Female ; Glucose ; Glycated Hemoglobin A ; Hospitals ; Humans ; Hypoglycemia ; Hypoglycemic agents ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - therapeutic use ; Insulin resistance ; Kidney diseases ; Kidneys ; Liver ; Liver diseases ; Male ; Medicine ; Medicine and Health Sciences ; Metabolism ; Middle Aged ; Nephrology ; Patients ; Pharmacology ; Pioglitazone ; Pioglitazone - administration & dosage ; Pioglitazone - adverse effects ; Pioglitazone - therapeutic use ; Renal Insufficiency, Chronic - blood ; Renal Insufficiency, Chronic - drug therapy ; Retention ; Side effects ; Systematic review ; Treatment Outcome ; Urine</subject><ispartof>PloS one, 2018-10, Vol.13 (10), p.e0206722-e0206722</ispartof><rights>2018 Satirapoj et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2018 Satirapoj et al 2018 Satirapoj et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c526t-a76fe6c679f62cbcf0ba1e5acede54273bdc128edf52445bf209bf2226217a133</citedby><cites>FETCH-LOGICAL-c526t-a76fe6c679f62cbcf0ba1e5acede54273bdc128edf52445bf209bf2226217a133</cites><orcidid>0000-0002-8881-0942</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209355/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209355/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30379936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Satirapoj, Bancha</creatorcontrib><creatorcontrib>Watanakijthavonkul, Khanin</creatorcontrib><creatorcontrib>Supasyndh, Ouppatham</creatorcontrib><title>Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Choices of hypoglycemic agents for patients with type 2 diabetes and chronic kidney disease (CKD) are limited. Available data among patients with CKD suggest that pioglitazone was effective and safe, with no increase in serious adverse effects. However, weight gain and fluid retention are major clinical problems for pioglitazone among patients with CKD. We conducted this study to compare the efficacy and side effects of low dose pioglitazone with standard dose pioglitazone among patients with type 2 diabetes and CKD.
A total of 75 patients with type 2 diabetes and CKD and inadequate glycemic control receiving any pharmacological antidiabetic treatment were randomly assigned to 2 groups. One group consisted of 37 patients treated with standard dose pioglitazone (15 mg/day) and another group consisted of 38 patients treated with low dose pioglitazone (7.5 mg/day). Glycosylated hemoglobinA1c (HbA1c) and metabolic profiles were monitored every 8 weeks for 24 weeks. Body composition was assessed using bio-electrical impedance analysis (BIA).
After 6 months of therapy, HbA1c levels decreased in both standard and low dose pioglitazone groups. The mean changes in HbA1c for standard and low dose pioglitazone were 1.1±1.6 and -1.4±1.5 (P = 0.543), respectively. Compared with low dose pioglitazone, standard dose pioglitazone treatment led to a greater increase in body weight, fat mass, total body water and extracellular water composition. No major adverse effects including hypoglycemia, congestive heart failure and abnormal liver function were identified.
Pioglitazone 7.5 mg once daily treatments presented similar glycemic control to standard dose pioglitazone and exhibited beneficial effects on weight gain and fluid retention among patients with type 2 diabetes and CKD.</description><subject>Aged</subject><subject>Antidiabetics</subject><subject>Bioelectricity</subject><subject>Biology and Life Sciences</subject><subject>Blood Glucose</subject><subject>Blood pressure</subject><subject>Blood tests</subject><subject>Body composition</subject><subject>Body composition (biology)</subject><subject>Body fat</subject><subject>Body water</subject><subject>Body weight</subject><subject>Body weight gain</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Composition effects</subject><subject>Congestive heart failure</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetic Nephropathies - blood</subject><subject>Diabetic Nephropathies - drug therapy</subject><subject>Disease control</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug dosages</subject><subject>Edema</subject><subject>Electrical impedance</subject><subject>Family medical history</subject><subject>Female</subject><subject>Glucose</subject><subject>Glycated Hemoglobin A</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Hypoglycemia</subject><subject>Hypoglycemic agents</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin resistance</subject><subject>Kidney diseases</subject><subject>Kidneys</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Metabolism</subject><subject>Middle Aged</subject><subject>Nephrology</subject><subject>Patients</subject><subject>Pharmacology</subject><subject>Pioglitazone</subject><subject>Pioglitazone - administration & dosage</subject><subject>Pioglitazone - adverse effects</subject><subject>Pioglitazone - therapeutic use</subject><subject>Renal Insufficiency, Chronic - blood</subject><subject>Renal Insufficiency, Chronic - drug therapy</subject><subject>Retention</subject><subject>Side effects</subject><subject>Systematic review</subject><subject>Treatment Outcome</subject><subject>Urine</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNptks9uEzEQxlcIREvhDRBY4tJLgv_senc5IFVVgUqVOABna9YeJw7OerEdqvR1eFEcklYt6sW2PN_3mxl7quo1o3MmWvZ-FTZxBD-fwohzyqlsOX9SHbNe8JnkVDy9dz6qXqS0orQRnZTPqyNBRdv3Qh5Xf76BxbwlMBqC1joNekuCJT5cExMSksmFhXcZbkoaosN6goiGXLu8JCkXF0TziNCNJG8nJJwYBwNmTHuLXsYwOk1-OjPitgQTQsIP5IzEwgprd1PgOow5Bu_LMUcH_mX1zIJP-Oqwn1Q_Pl18P_8yu_r6-fL87GqmGy7zDFppUWrZ9lZyPWhLB2DYgEaDTc1bMRjNeIfGNryum8Fy2peFc8lZC0yIk-rtnjv5kNThfZPijLeykZKxorjcK0yAlZqiW0PcqgBO_bsIcaEgZqc9KkM7o2kLYLmpu24YBiZFLxrBtOmh6wrr4yHbZlij0ViaBv8A-jAyuqVahN-qfGjhNAVwegDE8GuDKau1Sxq9hxHDZl93X3e03eV695_08e7qvUrHkFJEe1cMo2o3c7cutZs5dZi5Yntzv5E70-2Qib9_ltli</recordid><startdate>20181031</startdate><enddate>20181031</enddate><creator>Satirapoj, Bancha</creator><creator>Watanakijthavonkul, Khanin</creator><creator>Supasyndh, Ouppatham</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8881-0942</orcidid></search><sort><creationdate>20181031</creationdate><title>Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial</title><author>Satirapoj, Bancha ; Watanakijthavonkul, Khanin ; Supasyndh, Ouppatham</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c526t-a76fe6c679f62cbcf0ba1e5acede54273bdc128edf52445bf209bf2226217a133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Antidiabetics</topic><topic>Bioelectricity</topic><topic>Biology and Life Sciences</topic><topic>Blood Glucose</topic><topic>Blood pressure</topic><topic>Blood tests</topic><topic>Body composition</topic><topic>Body composition (biology)</topic><topic>Body fat</topic><topic>Body water</topic><topic>Body weight</topic><topic>Body weight gain</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Composition effects</topic><topic>Congestive heart failure</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetic Nephropathies - blood</topic><topic>Diabetic Nephropathies - drug therapy</topic><topic>Disease control</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug dosages</topic><topic>Edema</topic><topic>Electrical impedance</topic><topic>Family medical history</topic><topic>Female</topic><topic>Glucose</topic><topic>Glycated Hemoglobin A</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Hypoglycemia</topic><topic>Hypoglycemic agents</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin resistance</topic><topic>Kidney diseases</topic><topic>Kidneys</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Metabolism</topic><topic>Middle Aged</topic><topic>Nephrology</topic><topic>Patients</topic><topic>Pharmacology</topic><topic>Pioglitazone</topic><topic>Pioglitazone - administration & dosage</topic><topic>Pioglitazone - adverse effects</topic><topic>Pioglitazone - therapeutic use</topic><topic>Renal Insufficiency, Chronic - blood</topic><topic>Renal Insufficiency, Chronic - drug therapy</topic><topic>Retention</topic><topic>Side effects</topic><topic>Systematic review</topic><topic>Treatment Outcome</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Satirapoj, Bancha</creatorcontrib><creatorcontrib>Watanakijthavonkul, Khanin</creatorcontrib><creatorcontrib>Supasyndh, Ouppatham</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Satirapoj, Bancha</au><au>Watanakijthavonkul, Khanin</au><au>Supasyndh, Ouppatham</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2018-10-31</date><risdate>2018</risdate><volume>13</volume><issue>10</issue><spage>e0206722</spage><epage>e0206722</epage><pages>e0206722-e0206722</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Choices of hypoglycemic agents for patients with type 2 diabetes and chronic kidney disease (CKD) are limited. Available data among patients with CKD suggest that pioglitazone was effective and safe, with no increase in serious adverse effects. However, weight gain and fluid retention are major clinical problems for pioglitazone among patients with CKD. We conducted this study to compare the efficacy and side effects of low dose pioglitazone with standard dose pioglitazone among patients with type 2 diabetes and CKD.
A total of 75 patients with type 2 diabetes and CKD and inadequate glycemic control receiving any pharmacological antidiabetic treatment were randomly assigned to 2 groups. One group consisted of 37 patients treated with standard dose pioglitazone (15 mg/day) and another group consisted of 38 patients treated with low dose pioglitazone (7.5 mg/day). Glycosylated hemoglobinA1c (HbA1c) and metabolic profiles were monitored every 8 weeks for 24 weeks. Body composition was assessed using bio-electrical impedance analysis (BIA).
After 6 months of therapy, HbA1c levels decreased in both standard and low dose pioglitazone groups. The mean changes in HbA1c for standard and low dose pioglitazone were 1.1±1.6 and -1.4±1.5 (P = 0.543), respectively. Compared with low dose pioglitazone, standard dose pioglitazone treatment led to a greater increase in body weight, fat mass, total body water and extracellular water composition. No major adverse effects including hypoglycemia, congestive heart failure and abnormal liver function were identified.
Pioglitazone 7.5 mg once daily treatments presented similar glycemic control to standard dose pioglitazone and exhibited beneficial effects on weight gain and fluid retention among patients with type 2 diabetes and CKD.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>30379936</pmid><doi>10.1371/journal.pone.0206722</doi><orcidid>https://orcid.org/0000-0002-8881-0942</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2018-10, Vol.13 (10), p.e0206722-e0206722 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2127656611 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Aged Antidiabetics Bioelectricity Biology and Life Sciences Blood Glucose Blood pressure Blood tests Body composition Body composition (biology) Body fat Body water Body weight Body weight gain Clinical medicine Clinical trials Composition effects Congestive heart failure Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetic Nephropathies - blood Diabetic Nephropathies - drug therapy Disease control Dose-Response Relationship, Drug Drug dosages Edema Electrical impedance Family medical history Female Glucose Glycated Hemoglobin A Hospitals Humans Hypoglycemia Hypoglycemic agents Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Insulin resistance Kidney diseases Kidneys Liver Liver diseases Male Medicine Medicine and Health Sciences Metabolism Middle Aged Nephrology Patients Pharmacology Pioglitazone Pioglitazone - administration & dosage Pioglitazone - adverse effects Pioglitazone - therapeutic use Renal Insufficiency, Chronic - blood Renal Insufficiency, Chronic - drug therapy Retention Side effects Systematic review Treatment Outcome Urine |
| title | Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T01%3A24%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20efficacy%20of%20low%20dose%20pioglitazone%20compared%20with%20standard%20dose%20pioglitazone%20in%20type%202%20diabetes%20with%20chronic%20kidney%20disease:%20A%20randomized%20controlled%20trial&rft.jtitle=PloS%20one&rft.au=Satirapoj,%20Bancha&rft.date=2018-10-31&rft.volume=13&rft.issue=10&rft.spage=e0206722&rft.epage=e0206722&rft.pages=e0206722-e0206722&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0206722&rft_dat=%3Cproquest_plos_%3E2127948078%3C/proquest_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2127656611&rft_id=info:pmid/30379936&rft_doaj_id=oai_doaj_org_article_d08dc07aaf2d488bbb16393531cd9a88&rfr_iscdi=true |